SCHEMBL16447237

SCHEMBL16447237

[N-]=[N+]=NCCNC(=O)CCCCC[C@H](N)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NOD1 Q9Y239 3/20 0.49
▸ OTC P00480 1/20 0.47
▸ NOS2 P35228 6/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ DDAH1 O94760 3/20 0.41
▸ NOS1 P29475 4/20 0.40
▸ NOS3 P29474 3/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ GSR P00390 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ APEX1 P27695 1/20 0.40
▸ BLM P54132 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15618211 0.90 OTC (0.49) NOD1OTCNOS2TDP1DDAH1
SCHEMBL15483719 0.89 OTC (0.50) NOD1OTCNOS2TDP1DDAH1
SCHEMBL24610028 0.88 OTC (0.44) NOD1OTCNOS2DDAH1CYP1A2
SCHEMBL15469244 0.88 OTC (0.44) NOD1OTCNOS2DDAH1CYP1A2
SCHEMBL15618245 0.87 OTC (0.51) NOD1OTCNOS2TDP1DDAH1
SCHEMBL16446596 0.83 OTC (0.46) OTCNOS2DDAH1NOS1NOS3
SCHEMBL20178595 0.83 OTC (0.46) OTCNOS2DDAH1NOS1NOS3
SCHEMBL22508710 0.81 EPHX2 (0.45) TSHRNFKB1
SCHEMBL24767454 0.80 NOS2 (0.57) NOS2DDAH1NOS1NOS3CYP1A2
SCHEMBL16892792 0.80 NOS2 (0.57) NOS2DDAH1NOS1NOS3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030545-B1 AMINO ACID DERIVATIVES MEDIMMUNE LTD (GB) 2020-10-07 — — EP disclosed
US-9981908-B2 Amino acid derivatives MEDIMMUNE LIMITED (GB) 2018-05-29 — — US disclosed
US-9981908-B2 Amino acid derivatives MEDIMMUNE LIMITED (GB) 2018-05-29 — — US disclosed
US-20160176811-A1 Amino Acid Derivatives ALLOZYNE, INC. 2016-06-23 — — US disclosed
US-20160176811-A1 Amino Acid Derivatives ALLOZYNE, INC. 2016-06-23 — — US disclosed
EP-3030545-A2 AMINO ACID DERIVATIVES Medimmune Limited (GB) 2016-06-15 — — EP disclosed
WO-2015019192-A2 AMINO ACID DERIVATIVES MEDIMMUNE LIMITED (GB) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176811-A1 Amino Acid Derivatives BCAT2, BCAT1, DAO NOD1 3661/4885OTC 2283/4885NOS2 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback